CJC-1295 (No DAC) 10 mg, also known as Modified GRF (1-29), is a synthetic peptide designed to mimic the activity of endogenous growth hormone-releasing hormone (GHRH). Unlike DAC-modified variants, this form is characterized by a shorter duration of activity, making it suitable for research focused on pulsatile signaling patterns and receptor-level interactions in controlled laboratory environments.

In preclinical and in vitro studies, CJC-1295 (No DAC) has been examined for its interaction with GHRH receptors and its potential role in modulating growth hormone signaling pathways. Researchers have explored its effects on receptor binding activity, intracellular signaling cascades, and endocrine response mechanisms within experimental models. These investigations remain limited to laboratory and experimental conditions, and further research is required to fully understand its mechanisms and broader implications.

The 10 mg format supports standardized handling and precise measurement in research settings and should be used in accordance with appropriate laboratory protocols.

CJC-1295 (No DAC) is supplied exclusively for research and laboratory use. It is not approved by the U.S. Food and Drug Administration for any therapeutic or clinical applications. This product is not intended to diagnose, treat, cure, or prevent any disease and must not be used for human or veterinary consumption.

All handling should be conducted by qualified professionals in appropriate research facilities, following applicable regulatory and safety standards.